Loading clinical trials...
Loading clinical trials...
This is a phase 1/2 open-label, dose-escalation study investigating single-agent therapy with VELCADE in patients with previously treated systemic AL-amyloidosis who require further treatment.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Collaborators
NCT05451771 · AL Amyloidosis
NCT07583823 · Cardiac Amyloidosis, Pacemaker
NCT06563895 · Amyloidosis, Amyloid Cardiomyopathy, and more
NCT07266116 · Systemic Light Chain Amyloidosis
NCT06465810 · Transthyretin Amyloidosis, ATTR-CM, and more
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute
Los Angeles, California
Winship Cancer Center - Emory Clinic School of Medicine
Atlanta, Georgia
Boston Medical Center
Boston, Massachusetts
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions